TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton's Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-554-4484
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$150,000.00
Profitability
Miscellaneous
Employees105
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
TG Therapeutics (NASDAQ:TGTX) Frequently Asked Questions
What is TG Therapeutics' stock symbol?
TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."
How were TG Therapeutics' earnings last quarter?
TG Therapeutics Inc (NASDAQ:TGTX) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04. The biopharmaceutical company earned $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative return on equity of 245.97% and a negative net margin of 98,576.14%. View TG Therapeutics' Earnings History.
When is TG Therapeutics' next earnings date?
What price target have analysts set for TGTX?
6 analysts have issued twelve-month price objectives for TG Therapeutics' stock. Their forecasts range from $8.00 to $27.00. On average, they anticipate TG Therapeutics' share price to reach $15.6667 in the next twelve months. This suggests a possible upside of 100.1% from the stock's current price. View Analyst Price Targets for TG Therapeutics.
What is the consensus analysts' recommendation for TG Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TG Therapeutics.
What are Wall Street analysts saying about TG Therapeutics stock?
Here are some recent quotes from research analysts about TG Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our $20 price target is based on the net present value of our revenue forecast through 2027, applying a 40% probability of success (POS) for ublituximab in CLL, a 40% POS for umbralisib in CLL, a 30% POS for ublituximab in NHL, a 35% POS for umbralisib in 40% POS for ublituximab in MS." (4/12/2019)
- 2. According to Zacks Investment Research, "TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. " (4/6/2019)
- 3. Cantor Fitzgerald analysts commented, ". We are initiating coverage of TG Overweight rating and $17 12-month price target. We believe umbralisib (PI3K inhibitor) and ublituximab (anti-CD20) have attractive profiles in oncology and autoimmune B-cell diseases. We view both lead assets as clinically de-risked with proven targets, but we think investors are cautious on the PI3K commercial potential and give no credit to multiple sclerosis (MS) due to the competitive yet price sensitive landscape. Our thesis is that next-generation assets with a differentiated profile can gain share in late-stage lymphoma and that competing on price in MS with a similar drug can drive share." (3/29/2019)
Has TG Therapeutics been receiving favorable news coverage?
News articles about TGTX stock have trended positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. TG Therapeutics earned a news sentiment score of 2.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the stock's share price in the near term.
Are investors shorting TG Therapeutics?
TG Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totalling 17,293,162 shares, an increase of 31.2% from the February 28th total of 13,185,063 shares. Based on an average daily volume of 3,759,516 shares, the days-to-cover ratio is presently 4.6 days. Currently, 23.9% of the shares of the stock are short sold. View TG Therapeutics' Current Options Chain.
Who are some of TG Therapeutics' key competitors?
Some companies that are related to TG Therapeutics include Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Reata Pharmaceuticals (RETA), Insmed (INSM), Portola Pharmaceuticals (PTLA), Mirati Therapeutics (MRTX), Arena Pharmaceuticals (ARNA), PTC Therapeutics (PTCT), The Medicines (MDCO), Uniqure (QURE), AnaptysBio (ANAB) and Endocyte (ECYT).
What other stocks do shareholders of TG Therapeutics own?
Who are TG Therapeutics' key executives?
TG Therapeutics' management team includes the folowing people:
- Mr. Michael S. Weiss, Exec. Chairman, CEO & Pres (Age 53)
- Mr. Sean A. Power CPA, CFO, Corp. Sec. & Treasurer (Age 37)
- Jenna Bosco, VP of Investor Relations & Sr. VP of Corp. Communications
- Mr. Adam Waldman, Chief Commercial Officer
Who are TG Therapeutics' major shareholders?
TG Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Mycio Wealth Partners LLC (0.08%). Company insiders that own TG Therapeutics stock include Sean A Power and William James Kennedy. View Institutional Ownership Trends for TG Therapeutics.
Which institutional investors are buying TG Therapeutics stock?
How do I buy shares of TG Therapeutics?
Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TG Therapeutics' stock price today?
One share of TGTX stock can currently be purchased for approximately $7.83.
How big of a company is TG Therapeutics?
TG Therapeutics has a market capitalization of $688.81 million and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-173,480,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. TG Therapeutics employs 105 workers across the globe.
What is TG Therapeutics' official website?
How can I contact TG Therapeutics?
TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 212-554-4484 or via email at [email protected]
MarketBeat Community Rating for TG Therapeutics (NASDAQ TGTX)
MarketBeat's community ratings are surveys of what our community members think about TG Therapeutics and other stocks. Vote "Outperform" if you believe TGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
